Tags

Type your tag names separated by a space and hit enter

HOXB8 expression in ovarian serous carcinoma effusions is associated with shorter survival.
Gynecol Oncol. 2013 May; 129(2):358-63.GO

Abstract

OBJECTIVE

HOX proteins are key transcription factors in embryogenesis. HOXB5 and HOXB8 were previously shown to be overexpressed in ovarian/primary peritoneal serous carcinoma compared to breast carcinoma using gene expression arrays. The present study investigated the clinical role of HOXB5 and HOXB8 in advanced-stage (FIGO III-IV) ovarian serous carcinoma.

METHODS

HOXB5 and HOXB8 protein expression was analyzed in 286 effusions and 76 patient-matched solid lesions (27 primary carcinomas, 49 metastases) using immunohistochemistry. Expression was analyzed for association with clinicopathologic parameters, including survival.

RESULTS

Cytoplasmic HOXB5 protein was detected in 268/286 (94%) effusions. HOXB8 was expressed at both the cytoplasm (252/286; 88%) and nucleus (131/286; 46%) of carcinoma cells. Cytoplasmic HOXB5, cytoplasmic HOXB8 and nuclear HOXB8 were found in 56/76 (74%), 76/76 (100%) and 30/76 (39%) solid lesions, respectively, with significantly higher HOXB5 expression in effusions (p=0.002) and higher cytoplasmic HOXB8 in solid lesions (p<0.001). HOXB5 expression was higher in post-chemotherapy disease recurrence effusions compared to pre-chemotherapy effusions tapped at diagnosis (p=0.04). In univariate survival analysis of the effusion cohort, higher expression of cytoplasmic HOXB8 was associated with significantly shorter progression-free survival (p=0.033), whereas higher nuclear HOXB8 expression was associated with significantly shorter overall survival in analysis limited to patients with post-chemotherapy effusions (p=0.036). Neither finding was independent prognostic factor in Cox multivariate analysis.

CONCLUSIONS

HOXB5 and HOXB8 are frequently expressed in ovarian serous carcinoma, with anatomic site-related differences for cytoplasmic staining. HOXB5 may be affected by chemotherapy in effusions. HOXB8 expression is associated with shorter survival in metastatic serous carcinoma.

Authors+Show Affiliations

Division of Pathology, Norwegian Radium Hospital, Oslo University Hospital, N-0310 Oslo, Norway.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23438671

Citation

Stavnes, Helene Tuft, et al. "HOXB8 Expression in Ovarian Serous Carcinoma Effusions Is Associated With Shorter Survival." Gynecologic Oncology, vol. 129, no. 2, 2013, pp. 358-63.
Stavnes HT, Holth A, Don T, et al. HOXB8 expression in ovarian serous carcinoma effusions is associated with shorter survival. Gynecol Oncol. 2013;129(2):358-63.
Stavnes, H. T., Holth, A., Don, T., Kærn, J., Vaksman, O., Reich, R., Trope', C. G., & Davidson, B. (2013). HOXB8 expression in ovarian serous carcinoma effusions is associated with shorter survival. Gynecologic Oncology, 129(2), 358-63. https://doi.org/10.1016/j.ygyno.2013.02.021
Stavnes HT, et al. HOXB8 Expression in Ovarian Serous Carcinoma Effusions Is Associated With Shorter Survival. Gynecol Oncol. 2013;129(2):358-63. PubMed PMID: 23438671.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - HOXB8 expression in ovarian serous carcinoma effusions is associated with shorter survival. AU - Stavnes,Helene Tuft, AU - Holth,Arild, AU - Don,Trinh, AU - Kærn,Janne, AU - Vaksman,Olga, AU - Reich,Reuven, AU - Trope',Claes G, AU - Davidson,Ben, Y1 - 2013/02/21/ PY - 2012/12/03/received PY - 2013/02/12/revised PY - 2013/02/13/accepted PY - 2013/2/27/entrez PY - 2013/2/27/pubmed PY - 2013/6/12/medline SP - 358 EP - 63 JF - Gynecologic oncology JO - Gynecol Oncol VL - 129 IS - 2 N2 - OBJECTIVE: HOX proteins are key transcription factors in embryogenesis. HOXB5 and HOXB8 were previously shown to be overexpressed in ovarian/primary peritoneal serous carcinoma compared to breast carcinoma using gene expression arrays. The present study investigated the clinical role of HOXB5 and HOXB8 in advanced-stage (FIGO III-IV) ovarian serous carcinoma. METHODS: HOXB5 and HOXB8 protein expression was analyzed in 286 effusions and 76 patient-matched solid lesions (27 primary carcinomas, 49 metastases) using immunohistochemistry. Expression was analyzed for association with clinicopathologic parameters, including survival. RESULTS: Cytoplasmic HOXB5 protein was detected in 268/286 (94%) effusions. HOXB8 was expressed at both the cytoplasm (252/286; 88%) and nucleus (131/286; 46%) of carcinoma cells. Cytoplasmic HOXB5, cytoplasmic HOXB8 and nuclear HOXB8 were found in 56/76 (74%), 76/76 (100%) and 30/76 (39%) solid lesions, respectively, with significantly higher HOXB5 expression in effusions (p=0.002) and higher cytoplasmic HOXB8 in solid lesions (p<0.001). HOXB5 expression was higher in post-chemotherapy disease recurrence effusions compared to pre-chemotherapy effusions tapped at diagnosis (p=0.04). In univariate survival analysis of the effusion cohort, higher expression of cytoplasmic HOXB8 was associated with significantly shorter progression-free survival (p=0.033), whereas higher nuclear HOXB8 expression was associated with significantly shorter overall survival in analysis limited to patients with post-chemotherapy effusions (p=0.036). Neither finding was independent prognostic factor in Cox multivariate analysis. CONCLUSIONS: HOXB5 and HOXB8 are frequently expressed in ovarian serous carcinoma, with anatomic site-related differences for cytoplasmic staining. HOXB5 may be affected by chemotherapy in effusions. HOXB8 expression is associated with shorter survival in metastatic serous carcinoma. SN - 1095-6859 UR - https://www.unboundmedicine.com/medline/citation/23438671/HOXB8_expression_in_ovarian_serous_carcinoma_effusions_is_associated_with_shorter_survival_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0090-8258(13)00092-9 DB - PRIME DP - Unbound Medicine ER -